The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Détails

ID Serval
serval:BIB_FA16AC950873
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Périodique
Journal of thoracic oncology
Auteur(s)
Manegold C., Dingemans A.C., Gray J.E., Nakagawa K., Nicolson M., Peters S., Reck M., Wu Y.L., Brustugun O.T., Crinò L., Felip E., Fennell D., Garrido P., Huber R.M., Marabelle A., Moniuszko M., Mornex F., Novello S., Papotti M., Pérol M., Smit E.F., Syrigos K., van Meerbeeck J.P., van Zandwijk N., Chih-Hsin Yang J., Zhou C., Vokes E.
ISSN
1556-1380 (Electronic)
ISSN-L
1556-0864
Statut éditorial
Publié
Date de publication
02/2017
Peer-reviewed
Oui
Volume
12
Numéro
2
Pages
194-207
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Over the past few years, there have been considerable advances in the treatments available to patients with metastatic or locally advanced NSCLC, particularly those who have progressed during first-line treatment. Some of the treatment options available to patients are discussed here, with a focus on checkpoint inhibitor immunotherapies (nivolumab and pembrolizumab) and antiangiogenic agents (bevacizumab, ramucirumab, and nintedanib). It is hypothesized that combining immunotherapy with antiangiogenic treatment may have a synergistic effect and enhance the efficacy of both treatments. In this review, we explore the theory and potential of this novel treatment option for patients with advanced NSCLC. We discuss the growing body of evidence that proangiogenic factors can modulate the immune response (both by reducing T-cell infiltration into the tumor microenvironment and through systemic effects on immune-regulatory cell function), and we examine the preclinical evidence for combining these treatments. Potential challenges are also considered, and we review the preliminary evidence of clinical efficacy and safety with this novel combination in a variety of solid tumor types.

Mots-clé
Angiogenesis Inhibitors/therapeutic use, Carcinoma, Non-Small-Cell Lung/blood supply, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/immunology, Carcinoma, Non-Small-Cell Lung/pathology, Humans, Immunotherapy, Lung Neoplasms/blood supply, Lung Neoplasms/drug therapy, Lung Neoplasms/immunology, Lung Neoplasms/pathology, Antiangiogenesis, Combination therapy, NSCLC
Pubmed
Web of science
Création de la notice
19/10/2016 12:34
Dernière modification de la notice
20/08/2019 17:25
Données d'usage